TY - JOUR
T1 - Hight-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma
AU - Child, JA
AU - Morgan, GJ
AU - Davies, FE
AU - Owen, RG
AU - Bell, SE
AU - Hawkins, K
AU - Brown, J
AU - Drayson, Mark
AU - Selby, PJ
PY - 2004/1/1
Y1 - 2004/1/1
N2 - BACKGROUND: High-dose therapy with supporting autologous stem-cell transplantation remains a controversial treatment for cancer. In multiple myeloma, first-line regimens incorporating high-dose therapy yield higher remission rates than do conventional-dose treatments, but evidence that this translates into improved survival is limited. METHODS: In this multicenter study, the Medical Research Council Myeloma VII Trial, we randomly assigned 407 patients with previously untreated multiple myeloma who were younger than 65 years of age to receive either standard conventional-dose combination chemotherapy or high-dose therapy and an autologous stem-cell transplant. RESULTS: Among the 401 patients who could be evaluated, the rates of complete response were higher in the intensive-therapy group than in the standard-therapy group (44 percent vs. 8 percent, P
AB - BACKGROUND: High-dose therapy with supporting autologous stem-cell transplantation remains a controversial treatment for cancer. In multiple myeloma, first-line regimens incorporating high-dose therapy yield higher remission rates than do conventional-dose treatments, but evidence that this translates into improved survival is limited. METHODS: In this multicenter study, the Medical Research Council Myeloma VII Trial, we randomly assigned 407 patients with previously untreated multiple myeloma who were younger than 65 years of age to receive either standard conventional-dose combination chemotherapy or high-dose therapy and an autologous stem-cell transplant. RESULTS: Among the 401 patients who could be evaluated, the rates of complete response were higher in the intensive-therapy group than in the standard-therapy group (44 percent vs. 8 percent, P
UR - http://www.scopus.com/inward/record.url?scp=0037739753&partnerID=8YFLogxK
U2 - 10.1056/NEJMoa022340
DO - 10.1056/NEJMoa022340
M3 - Article
C2 - 12736280
SN - 1533-4406
VL - 348
SP - 1875
EP - 1883
JO - New England Journal of Medicine
JF - New England Journal of Medicine
IS - 19
ER -
